Virtual Meetings 2021

Meet The Professor: Optimizing the Selection and Sequencing of Therapy for Patients with Renal Cell Carcinoma

For more information, please contact us at Meetings@ResearchToPractice.com or (800) 233-6153.

PARTICIPATING FACULTY

Toni K Choueiri, MD
Director, Lank Center for Genitourinary Oncology
Department of Medical Oncology
Dana-Farber Cancer Institute
The Jerome and Nancy Kohlberg Professor of Medicine
Harvard Medical School
Boston, Massachusetts

Hans Hammers, MD, PhD
Eugene P Frenkel, MD Scholar in Clinical Medicine
Co-Leader, Kidney Cancer Program
Co-Leader, Experimental Therapeutics
Associate Professor, Internal Medicine
Division of Hematology and Oncology
UT Southwestern
Dallas, Texas

Thomas E Hutson, DO, PharmD
Director, GU Oncology Program
Co-Director, Urologic Cancer Research and Treatment Center
Texas Oncology
Charles A Sammons Cancer Center
Baylor University Medical Center
Professor of Medicine
Texas A&M HSC College of Medicine
Dallas, Texas

Eric Jonasch, MD
Professor of Medicine
Department of Genitourinary Medical Oncology
The University of Texas
MD Anderson Cancer Center
Houston, Texas

David F McDermott, MD
Chief, Medical Oncology
Beth Israel Deaconess Medical Center
Leader, Kidney Cancer Program
Dana-Farber/Harvard Cancer Center
Professor of Medicine
Harvard Medical School
Boston, Massachusetts



Robert J Motzer, MD
Attending Physician, Department of Medicine
Jack and Dorothy Byrne Chair in Clinical Oncology
Memorial Sloan Kettering Cancer Center
New York, New York

William K Oh, MD
Clinical Professor of Medicine
Icahn School of Medicine at Mount Sinai
The Tisch Cancer Institute
Mount Sinai Health System
New York, New York

Elizabeth R Plimack, MD, MS
Chief, Division of Genitourinary Medical Oncology
Director, Genitourinary Clinical Research
Professor, Department of Hematology/Oncology
Fox Chase Cancer Center, Temple Health
Philadelphia, Pennsylvania

Thomas Powles, MBBS, MRCP, MD
Professor of Genitourinary Oncology
Barts Cancer Institute
Director of Barts Cancer Centre
Queen Mary University of London
London, United Kingdom

Brian I Rini, MD
Chief of Clinical Trials
Vanderbilt-Ingram Cancer Center
Ingram Professor of Medicine
Division of Hematology/Oncology
Vanderbilt University Medical Center
Nashville, Tennessee

SERIES MODERATOR
Neil Love, MD
Research To Practice

Agenda

Each 1-hour session will be divided into topic modules focused on current management, emerging research and novel agents and strategies under active investigation for renal cell carcinoma. Each event will employ an identical format that will include the following elements:

  • Moderator Dr Neil Love and a featured participating clinical investigator
  • Discussion of participating faculty treatment recommendations
  • Review of available clinical research findings
  • Community oncologist video case presentations
  • Interactive audience polling and extensive Q&A

    MODULE 1: Optimizing Front-Line Decision-Making for Advanced Renal Cell Carcinoma (RCC)

    MODULE 2: Sequencing of Therapy for Patients with Relapsed/Refractory RCC; Novel Approaches Under Investigation

    MODULE 3: Practical Considerations with the Use of Immune Checkpoint Inhibitors and Tyrosine Kinase Inhibitors for Advanced RCC

Target Audience
This activity has been designed to meet the educational needs of medical and radiation oncologists, urologists and other allied healthcare professionals involved in the treatment of renal cell carcinoma (RCC).

Learning Objectives

  • Effectively apply research findings and other clinical and biologic factors in the best-practice selection of first-line therapy for patients with metastatic RCC (mRCC).
  • Recall the underlying research database supporting the FDA approval of anti-PD-1/anti-CTLA-4 combination therapy as first-line treatment for mRCC, and develop strategies to appropriately integrate this approach into patient care.
  • Appraise available clinical trial data evaluating approved and investigational anti-PD-1/ PD-L1 antibody/multikinase inhibitor combinations for previously untreated mRCC, and counsel patients about the risks and benefits of these novel regimens.
  • Develop a rational approach to the sequencing of systemic therapies for patients with advanced RCC that progresses on first-line treatment, incorporating multikinase inhibitors, mTOR inhibitors, immunotherapeutic agents and other formulations.
  • Recognize side effects and toxicities commonly associated with approved and investigational therapeutic approaches, and use this information to develop supportive care plans for patients with RCC receiving these agents and regimens.
  • Recall available and emerging data with other investigational agents and strategies currently in testing for RCC, and where applicable, refer eligible patients for clinical trial participation.

CME Credit Form
CME and ABIM MOC credit form links will be emailed to each participant within 5 business days of the activity.

Accreditation Statement
Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Credit Designation Statement
Research To Practice designates each live activity for a maximum of 1 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

American Board of Internal Medicine (ABIM) — Maintenance of Certification (MOC)
Successful completion of each CME activity, which includes participation in the evaluation component and a short post-test, enables the participant to earn up to 1 Medical Knowledge MOC point in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Please note, this program has been specifically designed for the following ABIM specialty: medical oncology.

Personal information and data sharing: Research To Practice aggregates deidentified user data for program-use analysis, program development, activity planning and site improvement. We may provide aggregate and deidentified data to third parties, including commercial supporters. We do not share or sell personally identifiable information to any unaffiliated third parties or commercial supporters. Please see our privacy policy at ResearchToPractice.com/Privacy-Policy for more information. For those clinicians wishing to receive ABIM MOC credit for attending, you will receive an email after the event with instructions.

Content Validation and Disclosures
Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education. We assess conflicts of interest with faculty, planners and managers of CME activities. Conflicts of interest are identified and resolved through a conflict of interest resolution process. In addition, all activity content is reviewed by both a member of the RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

FACULTYDr Hutson has no relevant conflicts of interest to disclose. The following faculty (and their spouses/partners) reported relevant conflicts of interest, which have been resolved through a conflict of interest resolution process:

Dr ChoueiriConsulting Agreements: AstraZeneca Pharmaceuticals LP, Bristol-Myers Squibb Company, Eisai Inc, EMD Serono Inc, Exelixis Inc, Lilly, Merck, Novartis, Pfizer Inc; Contracted Research: Exelixis Inc, GlaxoSmithKline. Dr HammersAdvisory Committee: ARMO BioSciences, Bristol-Myers Squibb Company, Corvus Pharmaceuticals, Exelixis Inc, Merck, Novartis, Pfizer Inc, Surface Oncology; Contracted Research: Bristol-Myers Squibb Company, Merck. Dr JonaschConsulting Agreements: Aveo Pharmaceuticals, Eisai Inc, Exelixis Inc, Merck, Novartis, Pfizer Inc; Contracted Research: Merck, Telix Pharmaceuticals; Data and Safety Monitoring Board/Committee: Pfizer Inc. Dr McDermottConsulting Agreements: Alkermes, Bristol-Myers Squibb Company, Calithera Biosciences, Eisai Inc, EMD Serono Inc, Iovance Biotherapeutics, Lilly, Merck, Pfizer Inc, Werewolf Therapeutics; Contracted Research: Alkermes, Bristol-Myers Squibb Company, Exelixis Inc, Genentech, a member of the Roche Group, Merck, Pfizer Inc, X4 Pharmaceuticals Inc. Dr MotzerConsulting Agreements: AstraZeneca Pharmaceuticals LP, Aveo Pharmaceuticals, Eisai Inc, EMD Serono Inc, Exelixis Inc, Genentech, a member of the Roche Group, Incyte Corporation, Lilly, Merck, Novartis, Pfizer Inc, Roche Laboratories Inc; Contracted Research: Bristol-Myers Squibb Company, Eisai Inc, Exelixis Inc, Genentech, a member of the Roche Group, Pfizer Inc. Dr OhConsulting Agreements: Advanced Accelerator Applications, Astellas, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Conjupro Bio-Pharmaceuticals, Curio Biotech SA, Janssen Biotech Inc, Merck, Sanofi Genzyme, TeneoBio, The Foundry LLC. Dr PlimackAdvisory Committee: Bristol-Myers Squibb Company, Calithera Biosciences, Genentech, a member of the Roche Group, Janssen Biotech Inc, MEI Pharma Inc, Merck, Pfizer Inc, Seagen Inc; Contracted Research: Astellas, Bristol-Myers Squibb Company, Genentech, a member of the Roche Group, Merck; Data and Safety Monitoring Board/Committee: AstraZeneca Pharmaceuticals LP, Infinity Pharmaceuticals Inc, Pfizer Inc. Dr PowlesAdvisory Committee: Astellas, AstraZeneca Pharmaceuticals LP, Bristol-Myers Squibb Company, Eisai Inc, Exelixis Inc, Incyte Corporation, Ipsen Biopharmaceuticals Inc, Johnson & Johnson Pharmaceuticals, Merck, Merck Serono, Merck Sharp & Dohme Corp, Novartis, Pfizer Inc, Roche Laboratories Inc, Seagen Inc; Contracted Research: Astellas, AstraZeneca Pharmaceuticals LP, Bristol-Myers Squibb Company, Eisai Inc, Exelixis Inc, Ipsen Biopharmaceuticals Inc, Johnson & Johnson Pharmaceuticals, Merck, Merck Serono, Merck Sharp & Dohme Corp, Novartis, Pfizer Inc, Roche Laboratories Inc, Seagen Inc; Travel/Accommodation/Expenses: AstraZeneca Pharmaceuticals LP, Ipsen Biopharmaceuticals Inc, Merck Sharp & Dohme Corp, Pfizer Inc, Roche Laboratories Inc. Dr RiniAdvisory Committee and Consulting Agreements: 3D Medicines Corporation, Alkermes, Aravive Inc, Arrowhead Pharmaceuticals Inc, Aveo Pharmaceuticals, Bristol-Myers Squibb Company, Compugen, Corvus Pharmaceuticals, Genentech, a member of the Roche Group, GlaxoSmithKline, Merck, Pfizer Inc, Shionogi Inc, Surface Oncology, Synthorx; Contracted Research: Aravive Inc, Arrowhead Pharmaceuticals Inc, AstraZeneca Pharmaceuticals LP, Bristol-Myers Squibb Company, Dragonfly Therapeutics, Exelixis Inc, F Hoffmann-La Roche Ltd, Immunomedics Inc, Incyte Corporation, Merck, Mirati Therapeutics, Pfizer Inc, Seagen Inc, Surface Oncology, Taris Biomedical.

SERIES MODERATOR — Dr Love is president and CEO of Research To Practice. Research To Practice receives funds in the form of educational grants to develop CME activities from the following companies: AbbVie Inc, Adaptive Biotechnologies Corporation, Agios Pharmaceuticals Inc, Alexion Pharmaceuticals, Amgen Inc, Array BioPharma Inc, a subsidiary of Pfizer Inc, Astellas, AstraZeneca Pharmaceuticals LP, Aveo Pharmaceuticals, Bayer HealthCare Pharmaceuticals, BeiGene Ltd, Blueprint Medicines, Boehringer Ingelheim Pharmaceuticals Inc, Bristol-Myers Squibb Company, Celgene Corporation, Clovis Oncology, Daiichi Sankyo Inc, Eisai Inc, Epizyme Inc, Exact Sciences Inc, Exelixis Inc, Five Prime Therapeutics Inc, Foundation Medicine, Genentech, a member of the Roche Group, Gilead Sciences Inc, GlaxoSmithKline, Grail Inc, Halozyme Inc, Helsinn Healthcare SA, ImmunoGen Inc, Incyte Corporation, Ipsen Biopharmaceuticals Inc, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, Jazz Pharmaceuticals Inc, Karyopharm Therapeutics, Kite, A Gilead Company, Lilly, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, Merck, Novartis, Novocure Inc, Oncopeptides, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, Sanofi Genzyme, Seagen Inc, Sumitomo Dainippon Pharma Oncology Inc, Taiho Oncology Inc, Takeda Oncology, Tesaro, A GSK Company, Turning Point Therapeutics Inc and Verastem Inc.

RESEARCH TO PRACTICE CME PLANNING COMMITTEE MEMBERS, STAFF AND REVIEWERS — Planners, scientific staff and independent reviewers for Research To Practice have no relevant conflicts of interest to disclose.

Supporters
These activities are supported by educational grants from Aveo Pharmaceuticals, Bristol-Myers Squibb Company, Eisai Inc and Exelixis Inc.